培氟沙星治疗细菌性下呼吸道感染的临床疗效评价  

Clinical Evaluation of Pefloxacin Mesylate in the Treatment of Bacterial Lower Respiratory Infections

作　　者：边长艳[1] 时淑华[1] 何茶叶[1] 

机构地区：[1]河南科技学院医院,河南新乡453003

出　　处：《保健医学研究与实践》2010年第4期39-41,共3页Health Medicine Research and Practice

摘　　要：目的评价培氟沙星治疗细菌性下呼吸道感染的临床疗效与安全性。方法将98例下呼吸道细菌感染患者随机分为2组,对照组(43例)以头孢哌酮钠-舒巴坦钠注射剂2.0g静脉滴注,每日2次;试验组(55例)给予甲磺酸培氟沙星注射剂0.4g,静脉滴注,每日2次,疗程均为7～10d。结果试验组和对照组的痊愈率分别为70.91%和72.09%,有效率分别为96.36%和93.02%;细菌清除率分别为96.55%和88.46%;不良反应发生率分别为5.45%和4.65%,两组间的差异均无统计学意义(P>0.05)。结论培氟沙星治疗常见的致病菌引起的下呼吸道感染,疗效确切,使用安全,为临床医师治疗下呼吸道感染时增加一种方法的选择,值得临床推广应用。Objective To evaluate the efficacy and safety of Pefloxacin mesylate treating with lower respiratory infections.Method 98 cases of lower respiratory infections were divided into 2 groups.The control group（43 cases）received intravehous dripping with Cefoperazone-sulbactam 2.0g;The test group（55 cases）received intravenous dripping with Pefloxacin mesylate 0.4g.The course of treatment was 7~10 days.Results The cure rates of test groups and the control groups were 70.91% and 72.09% respectively,and the effective rates were 96.36% and 93.02% respectively;The clearance rates of bacteria were 96.55% and 88.46% respectively;The adverse reaction rates were 5.45% and 4.65% respectively.The two groups showed no significant difference（P0.05）.Conclusion The pefloxacin has good efficacy and safety for the treatment of common lower respiratory infections caused by pathogens.Therefore,it is worthy of clinical popularization.

关 键 词：甲磺酸培氟沙星注射液 头孢哌酮钠-舒巴坦钠 下呼吸道感染 疗效 安全性 

分 类 号：R562[医药卫生—呼吸系统]